Bristol-Myers Squibb (NYSE:BMY – Get Score) EVP Ann Powell bought 25,000 shares of the corporate’s inventory in a transaction on Wednesday, September 14th. The inventory was bought at a mean worth of $70.75, for a complete transaction of $1,768,750.00. Following the completion of the transaction, the chief vp now owns 50,476 shares of the corporate’s inventory, valued at $3,571,177. The sale was disclosed in a authorized submitting with the Securities & Alternate Fee, which is accessible by way of this hyperlink.
Bristol-Myers Squibb Inventory Up 1.9 %
Shares of NYSE BMY traded up $1.31 throughout mid-day buying and selling on Thursday, hitting $71.78. 9,324,253 shares of the inventory traded fingers, in comparison with its common quantity of 13,189,522. The corporate has a debt-to-equity ratio of 1.14, a fast ratio of 1.34 and a present ratio of 1.44. Bristol-Myers Squibb has a 52 week low of $53.22 and a 52 week excessive of $80.59. The corporate has a market cap of $153.27 billion, a price-to-earnings ratio of 23.69, a PEG ratio of 1.51 and a beta of 0.43. The inventory has a fifty day shifting common worth of $72.64 and a 200-day shifting common worth of $73.94.
Bristol-Myers Squibb (NYSE:BMY – Get Score) final launched its quarterly earnings outcomes on Wednesday, July twenty seventh. The biopharmaceutical firm reported $1.93 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.14. Bristol-Myers Squibb had a return on fairness of 49.31% and a internet margin of 14.04%. The corporate had income of $11.89 billion for the quarter, in comparison with analyst estimates of $11.50 billion. Throughout the identical interval within the earlier 12 months, the corporate posted $1.93 earnings per share. The agency’s income was up 1.6% on a year-over-year foundation. Analysis analysts anticipate that Bristol-Myers Squibb will put up 7.5 EPS for the present 12 months.
Institutional Traders Weigh In On Bristol-Myers Squibb
Advert PressReach
Mr. Great’s DeFi Comeback
Digital forex firms dropped like flies, however this inventory nonetheless stands.
Hedge funds have just lately made adjustments to their positions within the firm. Mizuho Securities Co. Ltd. boosted its place in shares of Bristol-Myers Squibb by 239.0% throughout the first quarter. Mizuho Securities Co. Ltd. now owns 339 shares of the biopharmaceutical firm’s inventory valued at $25,000 after buying an extra 239 shares within the final quarter. Spectrum Administration Group LLC boosted its holdings in Bristol-Myers Squibb by 113.1% within the first quarter. Spectrum Administration Group LLC now owns 341 shares of the biopharmaceutical firm’s inventory price $25,000 after buying an extra 181 shares within the final quarter. Schubert & Co boosted its holdings in Bristol-Myers Squibb by 119.1% within the second quarter. Schubert & Co now owns 333 shares of the biopharmaceutical firm’s inventory price $26,000 after buying an extra 181 shares within the final quarter. Citadel Wealth Administration LLC purchased a brand new stake in Bristol-Myers Squibb within the second quarter price $26,000. Lastly, Nauset Wealth Administration. LLC purchased a brand new stake in Bristol-Myers Squibb within the first quarter price $27,000. 76.54% of the inventory is at the moment owned by institutional buyers.
Wall Road Analysts Forecast Development
A number of analysis companies have issued experiences on BMY. Atlantic Securities upped their worth goal on shares of Bristol-Myers Squibb from $83.00 to $87.00 and gave the corporate an “chubby” ranking in a analysis report on Monday. Citigroup restated a “purchase” ranking and set a $90.00 worth goal on shares of Bristol-Myers Squibb in a analysis report on Friday, June third. Berenberg Financial institution lowered shares of Bristol-Myers Squibb from a “purchase” ranking to a “maintain” ranking and lower their worth goal for the corporate from $82.00 to $76.00 in a analysis report on Wednesday. BMO Capital Markets upped their worth goal on shares of Bristol-Myers Squibb from $92.00 to $94.00 and gave the corporate an “outperform” ranking in a analysis report on Monday. Lastly, Financial institution of America upped their worth goal on shares of Bristol-Myers Squibb from $78.00 to $80.00 and gave the corporate a “purchase” ranking in a analysis notice on Monday, June sixth. One analysis analyst has rated the inventory with a promote ranking, 5 have given a maintain ranking, six have issued a purchase ranking and one has assigned a powerful purchase ranking to the inventory. In response to MarketBeat.com, Bristol-Myers Squibb presently has a consensus ranking of “Average Purchase” and a mean worth goal of $76.36.
Bristol-Myers Squibb Firm Profile
(Get Score)
Bristol-Myers Squibb Firm discovers, develops, licenses, manufactures, and markets biopharmaceutical merchandise worldwide. It gives merchandise for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 ailments. The corporate’s merchandise embody Revlimid, an oral immunomodulatory drug for the therapy of a number of myeloma; Eliquis, an oral inhibitor for discount in danger of stroke/systemic embolism in NVAF, and for the therapy of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for sufferers with a number of myeloma; and Orencia for grownup sufferers with energetic RA and psoriatic arthritis.
Featured Articles
This prompt information alert was generated by narrative science know-how and monetary knowledge from MarketBeat in an effort to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial crew previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you contemplate Bristol-Myers Squibb, you will wish to hear this.
MarketBeat retains monitor of Wall Road’s top-rated and finest performing analysis analysts and the shares they suggest to their shoppers every day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Bristol-Myers Squibb wasn’t on the listing.
Whereas Bristol-Myers Squibb at the moment has a “Maintain” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.
View The 5 Shares Right here
